Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Debt / NOTE 2.250% 2/0
-
Market price (% of par)
-
90.0%
-
Total 13F principal
-
$692,365,423
-
Principal change
-
+$64,634,899
-
Total reported market value
-
$625,022,314
-
Number of holders
-
41
-
Value change
-
+$61,677,589
-
Number of buys
-
24
-
Number of sells
-
17
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 as of Q1 2025
As of 31 Mar 2025,
BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 was held by
41 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$692,365,423
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, Voya Investment Management LLC, BRAIDWELL LP, WOLVERINE ASSET MANAGEMENT LLC, Davidson Kempner Capital Management LP, ARISTEIA CAPITAL, L.L.C., MACKAY SHIELDS LLC, SONA ASSET MANAGEMENT (US) LLC, WELLS FARGO & COMPANY/MN, and AMERIPRISE FINANCIAL INC.
This page lists
41
institutional bondholders reporting positions
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.